Artivion (AORT) | Financial Analysis & Statements
Artivion Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
116.0M
Gross Profit
73.1M
63.06%
Operating Income
7.2M
6.19%
Net Income
2.4M
2.09%
EPS (Diluted)
$0.05
Balance Sheet Metrics
Total Assets
884.8M
Total Liabilities
436.6M
Shareholders Equity
448.2M
Debt to Equity
0.97
Cash Flow Metrics
Operating Cash Flow
9.7M
Free Cash Flow
-7.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Artivion Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 441.3M | 388.5M | 354.0M | 313.8M | 298.8M |
| Cost of Goods Sold | 157.1M | 139.8M | 124.8M | 111.3M | 101.3M |
| Gross Profit | 284.2M | 248.8M | 229.2M | 202.5M | 197.5M |
| Gross Margin % | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% |
| Operating Expenses | |||||
| Research & Development | 31.0M | 28.5M | 28.7M | 38.9M | 35.5M |
| Selling, General & Administrative | 226.5M | 181.5M | 209.0M | 157.4M | 169.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 257.5M | 209.9M | 237.7M | 196.3M | 205.3M |
| Operating Income | 26.7M | 38.9M | -8.5M | 6.2M | -7.8M |
| Operating Margin % | 6.1% | 10.0% | -2.4% | 2.0% | -2.6% |
| Non-Operating Items | |||||
| Interest Income | 763.0K | 1.5M | 1.1M | 147.0K | 79.0K |
| Interest Expense | 26.6M | 34.3M | 25.3M | 18.2M | 16.9M |
| Other Non-Operating Income | 13.9M | -13.6M | 11.1M | -3.1M | 9.8M |
| Pre-tax Income | 14.8M | -7.5M | -21.6M | -15.0M | -14.8M |
| Income Tax | 5.0M | 5.8M | 9.1M | 4.2M | 7.0K |
| Effective Tax Rate % | 33.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 9.8M | -13.4M | -30.7M | -19.2M | -14.8M |
| Net Margin % | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% |
| Key Metrics | |||||
| EBITDA | 59.5M | 54.6M | 12.5M | 25.7M | 10.1M |
| EPS (Basic) | - | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| EPS (Diluted) | - | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| Basic Shares Outstanding | - | 41676000 | 40743000 | 40032000 | 38983000 |
| Diluted Shares Outstanding | - | 41676000 | 40743000 | 40032000 | 38983000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Artivion Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 64.9M | 53.5M | 58.9M | 39.4M | 55.0M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 89.8M | 79.5M | 71.8M | 61.8M | 53.0M |
| Inventory | 92.4M | 79.8M | 82.0M | 74.5M | 77.0M |
| Other Current Assets | 42.5M | 19.3M | 15.8M | 17.6M | 14.7M |
| Total Current Assets | 358.1M | 290.1M | 280.7M | 247.3M | 247.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 34.7M | 39.7M | 43.8M | 41.9M | 58.1M |
| Goodwill | 664.7M | 638.3M | 666.9M | 669.9M | 701.5M |
| Intangible Assets | 156.5M | 156.4M | 172.2M | 182.6M | 201.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 16.4M | 25.6M | 10.0M | 8.7M | 10.6M |
| Total Non-Current Assets | 526.7M | 499.0M | 511.7M | 515.5M | 545.4M |
| Total Assets | 884.8M | 789.1M | 792.4M | 762.8M | 793.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 16.0M | 18.0M | 13.3M | 12.0M | 10.4M |
| Short-term Debt | 5.4M | 5.3M | 5.4M | 5.4M | 5.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 25.5M | 583.0K | 2.4M | 1.3M | 1.1M |
| Total Current Liabilities | 101.6M | 66.8M | 57.9M | 49.7M | 45.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 252.2M | 357.0M | 352.9M | 351.4M | 356.7M |
| Deferred Tax Liabilities | 24.3M | 20.2M | 21.9M | 24.5M | 28.8M |
| Other Non-Current Liabilities | 49.0M | 60.9M | 71.2M | 47.4M | 55.9M |
| Total Non-Current Liabilities | 335.0M | 446.1M | 452.8M | 428.8M | 447.4M |
| Total Liabilities | 436.6M | 512.9M | 510.6M | 478.5M | 492.3M |
| Equity | |||||
| Common Stock | 493.0K | 434.0K | 426.0K | 418.0K | 414.0K |
| Retained Earnings | -51.5M | -61.3M | -47.9M | -17.2M | 2.0M |
| Treasury Stock | 14.6M | 14.6M | 14.6M | 14.6M | 14.6M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 448.2M | 276.2M | 281.8M | 284.3M | 300.7M |
| Key Metrics | |||||
| Total Debt | 257.6M | 362.3M | 358.3M | 356.8M | 362.0M |
| Working Capital | 256.5M | 223.3M | 222.8M | 197.7M | 202.7M |
Balance Sheet Composition
Artivion Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 9.8M | -13.4M | -30.7M | -19.2M | -14.8M |
| Depreciation & Amortization | 22.5M | 24.2M | 23.1M | 22.4M | 24.0M |
| Stock-Based Compensation | 24.4M | 14.2M | 14.4M | 12.3M | 10.7M |
| Working Capital Changes | -20.4M | -12.0M | -16.7M | -23.7M | -31.8M |
| Operating Cash Flow | 41.1M | 19.3M | 27.8M | -7.3M | 4.4M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | - | - | -5.0M | 0 | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | 0 | 19.0M |
| Investing Cash Flow | -3.0M | -17.0M | 6.9M | -1.7M | 19.7M |
| Financing Activities | |||||
| Share Repurchases | 0 | 0 | -559.0K | -1.8M | -1.9M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 212.5M | - | 0 | 0 |
| Debt Repayment | -2.5M | -212.9M | -5.3M | -2.8M | -3.1M |
| Financing Cash Flow | -4.0M | -4.6M | -5.6M | -5.0M | -16.0M |
| Free Cash Flow | 839.0K | 11.0M | 11.4M | -14.2M | -16.6M |
| Net Change in Cash | 34.1M | -2.2M | 29.1M | -14.0M | 8.2M |
Cash Flow Trend
Artivion Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
179.71
Forward P/E
32.65
Price to Book
4.03
Price to Sales
4.15
PEG Ratio
-1.59
Profitability Ratios
Profit Margin
2.21%
Operating Margin
8.09%
Return on Equity
2.70%
Return on Assets
2.34%
Financial Health
Current Ratio
3.53
Debt to Equity
57.67
Beta
1.62
Per Share Data
EPS (TTM)
$0.21
Book Value per Share
$9.37
Revenue per Share
$9.74
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AORT | 1.8B | 179.71 | 4.03 | 2.70% | 2.21% | 57.67 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Axogen | 1.9B | -110.18 | 13.15 | -13.49% | -6.97% | 55.50 |
| Establishment Labs | 1.9B | -37.89 | 79.68 | -133.25% | -24.19% | 1,123.15 |
| AdaptHealth | 1.7B | 16.64 | 1.11 | -4.25% | -2.18% | 124.67 |
Financial data is updated regularly. All figures are in the company's reporting currency.






